Tafasitamab and Lenalidomide as First Salvage Therapy for Residual Large B Cell Lym

The purpose of the study is to evaluate the safety and efficacy of tafasitamab and lenalidomide in participants with Large B Cell Lymphoma (LBCL) after axicabtagene ciloleucel (axi-cel) treatment. Participants will be asked to spend about 12 months in this study.

Trial Details

NCT ID
NCT06760156
Phase
PHASE2
Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • Tafasitamab
  • Lenalidomide
Locations (sample)
  • Tampa, Florida, United States|27.94752,-82.45843

Key Eligibility Criteria

  • Patients must have histologically documented history of large B-cell lymphoma, including diffuse large B-cell lymphoma (DLBCL) not otherwise specif…
  • Adult males or females must be of age ≥18 years or older at time of signing informed consent.
  • Patients must be capable of understanding the protocol with willingness to comply with all study procedures including availability for the duration…
  • Patients must be able to understand and willing to sign a written informed consent form (ICF) document.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →